Methamphetamine AbuseNCT05971043
Skin Disease in Methamphetamine Abuse
An observational study of Methamphetamine Abuse, run by Assiut University.
Trial summary
1. To detect the skin diseases in patients using methamphetamine Read more about this study
- Who is it for?
- Ages 14 to 75 years
- Conditions the study is for
- Methamphetamine Abuse
- How many people
- 500 participants
- Where
- No sites listed yet
- Study dates
- 3 Aug 2023to 20 Sep 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 14 to 75 years
- All sexes
- Child, Adult, Older adult
Study population: cross-sectional, questionnaire-based, study including clinical assessment of diseases severity.
Who may be able to join
- Patients using methamphetamine
Who cannot join
- 1. Pregnant and lactating patients. 2. Patients with chronic diseases
Trial locations and contacts
No sites are listed yet.
About this study
Official title: Skin Disorders in Patients Using Methamphetamine
- To detect the skin diseases in patients using methamphetamine
Read the detailed description
Methamphetamine is a stimulant drug that associated with a broad spectrum of health conditions, include addiction, mental health disorders, and overdose. The Drug Enforcement Agency (DEA) classifies it as a Schedule II drug. This means that the drug has a high potential for misuse. The drug is also called crystal meth, ice, and blue.
Methamphetamine use has increased in Egypt especially in upper Egypt. Literature on cutaneous manifestations among methamphetamine users is limited, although cellulitis, delusion of parasitosis (DOP), hyperhidrosis, formication and prurigo nodularis (PN) have been attributed to methamphetamine users. While the relationship between skin lesions and substance use in not fully defined, there is some evidence that points to the development of these itchy, red lesion also known as meth sore after meth use. Meth sores often look like small round red patches on your skin, they can often be confused with acne when they appear on the face or a rash when they appear on other parts of the body.
Meth sores form as a result of heavy meth misuse. other signs of meth abuse at the stage where sores likely to develop include:
- Weight loss
- Paranoia
- Hallucinations
- Aggressive behavior
- Being easily distracted
- Tooth and gum decay
- Changes in brain structure
- Conditions
- Methamphetamine Abuse
What is being measured
The primary outcome is the main question the study is designed to answer.
skin disorders in patients using methamphetamine
questionnaire-based study To detect the skin diseases and manifestation appears in patients using methamphetamine
Measured: baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Aug 2023
- Study start3 Aug 2023 (estimated)
- Primary completion20 Aug 2024 (estimated)
- Study completion20 Sep 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Methamphetamine AbuseStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 500 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Asmaa mohamed hafez, Assiut University
- Investigators
- Ahmed Shawkey gomaa, Lecturer, Study director, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05971043
- Sponsor's protocol ID
- meth addiction
- Status last verified
- Jul 2023
- First submitted
- 9 Jul 2023
- Last updated
- 2 Aug 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Barnes AJ, Smith ML, Kacinko SL, Schwilke EW, Cone EJ, Moolchan ET, Huestis MA. Excretion of methamphetamine and amphetamine in human sweat following controlled oral methamphetamine administration. Clin Chem. 2008 Jan;54(1):172-80. doi: 10.1373/clinchem.2007.092304. Epub 2007 Nov 2.
PubMed 17981924
Study at a glance
From the registry record, last updated by the sponsor on 2 Aug 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Skin Disorders in Patients Using Methamphetamine
- ClinicalTrials.gov ID
- NCT05971043
- Acronym / sponsor ID
- meth addiction
- Conditions
- Methamphetamine Abuse
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 500 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 3 Aug 2023 (estimated)
- Primary completion
- 20 Aug 2024 (estimated)
- Study completion
- 20 Sep 2024 (estimated)
- First posted
- 2 Aug 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
- To detect the skin diseases in patients using methamphetamine
Detailed description
Methamphetamine is a stimulant drug that associated with a broad spectrum of health conditions, include addiction, mental health disorders, and overdose. The Drug Enforcement Agency (DEA) classifies it as a Schedule II drug. This means that the drug has a high potential for misuse. The drug is also called crystal meth, ice, and blue.
Methamphetamine use has increased in Egypt especially in upper Egypt. Literature on cutaneous manifestations among methamphetamine users is limited, although cellulitis, delusion of parasitosis (DOP), hyperhidrosis, formication and prurigo nodularis (PN) have been attributed to methamphetamine users. While the relationship between skin lesions and substance use in not fully defined, there is some evidence that points to the development of these itchy, red lesion also known as meth sore after meth use. Meth sores often look like small round red patches on your skin, they can often be confused with acne when they appear on the face or a rash when they appear on other parts of the body.
Meth sores form as a result of heavy meth misuse. other signs of meth abuse at the stage where sores likely to develop include:
- Weight loss
- Paranoia
- Hallucinations
- Aggressive behavior
- Being easily distracted
- Tooth and gum decay
- Changes in brain structure
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Ages
- 14 to 75 years
- Sex
- All
- Age groups
- Child, Adult, Older adult
- Study population
- cross-sectional, questionnaire-based, study including clinical assessment of diseases severity.
Key inclusion criteria (1 listed)
- Patients using methamphetamine
Key exclusion criteria (1 listed)
- 1. Pregnant and lactating patients. 2. Patients with chronic diseases
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
skin disorders in patients using methamphetamine
Time frame: baseline
questionnaire-based study To detect the skin diseases and manifestation appears in patients using methamphetamine
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Aug 2023.
- Background: PubMed 17981924Barnes AJ, Smith ML, Kacinko SL, Schwilke EW, Cone EJ, Moolchan ET, Huestis MA. Excretion of methamphetamine and amphetamine in human sweat following controlled oral methamphetamine administration. Clin Chem. 2008 Jan;54(1):172-80. doi: 10.1373/clinchem.2007.092304. Epub 2007 Nov 2.
- Individual participant dataSharing planned: No
Related trials for Methamphetamine Abuse
RecruitingPhase 2
A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamine
Methamphetamine Intoxication, Methamphetamine Disorders
Recruiting
rTMS for Craving in Methamphetamine Use Disorder
Methamphetamine Abuse, Substance Use Disorders
RecruitingObservational study
Psychiatric Symptom Characteristics in Methamphetamine-Induced Psychosis With and Without Lifetime Cannabis Use
Methamphetamine Induced Psychosis, Cannabis Use
Active, not recruitingPhase 3
Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder
Methamphetamine-dependence, Methamphetamine Abuse
Recruiting
Data2Action Oregon Project: Supporting Data-driven Decision-Making for Substance Use Services, Policy, and Overdose Prevention
Substance Abuse, Decision Making, Shared
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ahmed Shawkey gomaa, Lecturer study director
Assiut University
Questions about this trial
What is this clinical trial studying?
An observational study of Methamphetamine Abuse, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 2 Aug 2023. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact asmaa mohamed, master (+201097507017, amelnakeeb@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
skin disorders in patients using methamphetamine (time frame: baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05971043, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Aug 2023.